Wall Street analyst estimates for TransCode Therapeutics, Inc. (RNAZ): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | |||
| 2026-08-14 | $-7.17 | ||
| 2026-05-15 | $-21.28 | ||
| 2026-04-15 | $-18.58 | $-10.08 | -84.3% |
| 2025-11-14 | $-5.49 | $-9.24 | +40.6% |
| 2025-08-14 | $-4.94 | $-8.68 | +43.1% |
| 2025-05-21 | $-70.28 | $-2.00 | -3414.0% |
| 2025-04-07 | $-8.50 | $-3.21 | -164.8% |
Valuation Ratios
| Price / Book | 0.01 |
| EV / EBITDA | 0.13 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $42470 | $98606 | $516746 | $534857 | 0 |
| Gross Profit | 0 | 0 | 0 | -$42470 | -$98606 | -$516746 | -$534857 | 0 |
| Research & Development | $82532 | $226309 | $284459 | $2.8M | $10.2M | $12.3M | $9.6M | $13.4M |
| Selling, General & Admin | $301464 | $230556 | $442145 | $3.4M | $8.3M | $6.6M | $5.5M | $5.8M |
| Operating Expenses | $384518 | $456865 | $726604 | $6.1M | $18.6M | $18.9M | $15.1M | $28.0M |
| Operating Income | -$383996 | -$456865 | -$726604 | -$6.2M | -$18.7M | -$19.4M | -$15.7M | -$28.0M |
| EBITDA | -$69444 | -$450247 | -$1.9M | -$6.7M | -$17.5M | -$18.0M | -$16.2M | -$34.3M |
| Interest Expense | 0 | $156965 | $394573 | $95070 | $17.6M | $55899 | $26813 | $6616 |
| Pre-tax Income | -$453440 | -$607212 | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $226068 |
| Net Income | -$453440 | -$607212 | -$2.3M | -$6.8M | -$17.6M | -$18.5M | -$16.8M | -$34.7M |
| EPS | $-2359.09 | $-72.00 | $-293.76 | $-648.00 | $-73187.37 | $-3453.65 | $-47.14 | $-52.59 |
| EPS (Diluted) | $-2359.09 | $-72.00 | $-293.76 | $-648.00 | $-1080.00 | $-3453.53 | $-47.14 | $-52.59 |
| Shares Outstanding (Diluted) | $192 | $6407 | $7979 | $10532 | $16221 | $5424 | $356115 | $689713 |
Price
| Price | $1.68 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · APVO · BOLT · GLTO · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of RNAZ: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks